2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Lymphoma, Large B-Cell, Diffuse
416
Lymphoma
406
Lymphoma, Non-Hodgkin
344
Leukemia, Lymphocytic, Chronic, B-Cell
313
Lymphoma, Follicular
301
Lymphoma, Mantle-Cell
226
Lymphoma, B-Cell, Marginal Zone
161
Leukemia
119
Lymphoma, B-Cell
112
Burkitt Lymphoma
110
Waldenstrom Macroglobulinemia
99
Precursor Cell Lymphoblastic Leukemia-Lymphoma
90
Recurrence
85
Hodgkin Disease
60
Lymphoma, Large-Cell, Immunoblastic
57
Neoplasms
39
Multiple Myeloma
26
Lymphoma, Large-Cell, Anaplastic
26
Myelodysplastic Syndromes
25
Leukemia, Myeloid, Acute
24
Hematologic Neoplasms
22
Dendritic Cell Sarcoma, Interdigitating
22
Leukemia, Hairy Cell
20
Intraocular Lymphoma
17
Leukemia, Prolymphocytic
16
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
14
Lymphoma, T-Cell
14
Neoplasms, Plasma Cell
13
Hematologic Diseases
13
Lymphoproliferative Disorders
12
Interventions
ofatumumab
1
daratumumab
1
Transcranial Direct Current Stimulation
1
Salpingo-oophorectomy
1
Rituximab
1
Magnetic Resonance Imaging
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
×
Rituximab
×
Clear all
NCT03274375
2023-07-13
IANMDAR
Assistance Publique - Hôpitaux de Paris
Phase 2
Recruiting
20 enrolled